sofosbuvir has been researched along with raltegravir potassium in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blackard, JT; Horn, PS; Karns, R; Kong, L; Kottilil, S; Rouster, SD; Shata, MT; Sherman, KE | 1 |
1 other study(ies) available for sofosbuvir and raltegravir potassium
| Article | Year |
|---|---|
CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
Topics: CCR5 Receptor Antagonists; Cell Line; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imidazoles; Maraviroc; Raltegravir Potassium; Receptors, CCR5; Sofosbuvir; Sulfoxides; Virus Replication | 2019 |